HEPARIN CALCIUM

also known as Unfractionated Heparin · UFH · Calciparine · Ecasolv · Heparin calcium salt · Heparinum calcicum · Héparine Sodique Choay · Unfractionated Heparin, LEO laboratories Ltd, MA #PL 0043/0041R · +1 more

Other / unclassified targets SERPINC1 via activation

Developed for: COVID-19 · venous thromboembolism · infectious disease with sepsis · blood coagulation disease · pneumonia · pulmonary embolism · ST-elevation myocardial infarction · coronary artery disorder
+26 more
· severe acute respiratory syndrome · acquired aneurysmal subarachnoid hemorrhage · acute chest syndrome · acute pancreatitis · acute respiratory distress syndrome · arterial occlusion · basilar artery occlusion · cardiovascular disorder · developmental delay, behavioral abnormalities, and neuropsychiatric disorders · end stage renal failure · gram-negative bacterial infections · lung disorder · myocardial infarction · respiratory failure · stroke disorder · thrombotic disease · viral pneumonia · acute coronary syndrome · acute myocardial infarction · atrial fibrillation · carotid artery dissection · chronic renal failure syndrome · hemorrhagic disease · intermediate coronary syndrome · ischemic disease · vertebral artery dissection
Investigated by: Australian National University · Canadian Institutes of Health Research (CIHR) · University of Manitoba · University of Sao Paulo General Hospital · Canadian Critical Care Trials Group · GlaxoSmithKline
+143 more
· Hamilton Health Sciences Corporation · St Vincent's Hospital Melbourne · Unity Health Toronto · University of Alberta · University of Sao Paulo · University of Vermont Medical Center · Xiaotong Hou · Academic Medical Center - University of Amsterdam · Al Ain Hospital · Alberta Health services · Allied Hospital Faisalabad · Anlu Puai Hospital · Assistance Publique - Hôpitaux de Paris · Aurora Clinical Research · Avanti PC · Barnes-Jewish Hospital · Beaumont Hospital · Beijing Anzhen Hospital · Beneficência Portuguesa de São Paulo · Beni-Suef University · Brazilian Clinical Research Institute · Brazilian Research In Intensive Care Network · Caidian District People's Hospital · Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · CancerCare Manitoba · Central South University · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Changjiang Shipping General Hospital · Chen Jing · Chibi People's Hospital · China Resources Wugang General Hospital · Chinese Academy of Medical Sciences, Fuwai Hospital · Clinica San Camilo, Argentina · Craig Seaman · D'Or Institute for Research and Education · Damanhour University · Dr Cipto Mangunkusumo General Hospital · Dr. Moewardi General Hospital, Surakarta, Indonesia · Dutch Burns Foundation · Ezhou Central Hospital · Foothills Medical Centre · Frederick Health · German Heart Center Munich · Groupe Hospitalier Pitie-Salpetriere · Hanyang University · Heart and Stroke Foundation of Ontario · Helwan University · Hopital Charles Lemoyne · Hospices Civils de Lyon · Hospital Alemão Oswaldo Cruz · Hospital Israelita Albert Einstein · Hospital Moinhos de Vento · Hospital Sirio-Libanes · Hospital do Coracao · Hubei University of Medicine · Indiana University · Indonesia University · Instituto Nacional de Cardiologia Ignacio Chavez · Jiangling People's Hospital · Jiangxia First People's Hospital · Jingzhou Central Hospital · John Hunter Hospital · King Fahad Medical City · King Faisal Specialist Hospital & Research Center · King Saud Medical City · Kristian Karstoft · Lady Reading Hospital, Pakistan · Laohekou First Hospital · MOUNT SINAI HOSPITAL · Maisonneuve-Rosemont Hospital · Marija Malgaj Vrečko · Massimo Girardis · Mater Misericordiae University Hospital · McMaster University · all 149 on the full record

Trials 52

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT06517563	Aug → Dec 2024	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT01513200	Jan → Feb 2012	—	Stealth BioTherapeutics Inc.	Completed	No outcome recorded
Phase 28 trials
Phase 2	NCT04313790	Aug 2020 → Oct 2022	infectious disease with sepsis	Damanhour University	Completed	No outcome recorded
Phase 2	NCT04466670	Jul 2020 → Dec 2021	COVID-19	University of Sao Paulo General Hospital	Unknown	No outcome recorded
Phase 2	NCT04344756	Apr → Jul 2020	pneumonia	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 2	NCT03378466	Mar 2018 → Dec 2021	infectious disease with sepsis	University of Manitoba	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02501434	Apr 2016 → Jan 2023	acquired aneurysmal subarachnoid hemorrhage, brain aneurysm, developmental delay, behavioral abnormalities, and neuropsychiatric disorders, heparin-induced thrombocytopenia +1	Robert F. James	Suspended	No outcome recorded
Phase 2	NCT02098993	May 2014 → Jun 2018	acute chest syndrome, sickle cell disease	Craig Seaman	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01648036	Jul 2012 → Jan 2014	infectious disease with sepsis	University of Manitoba	Completed	No outcome recorded
Phase 2	NCT00133731	Sep 2004 → Oct 2005	—	Sanofi	Completed	No outcome recorded
Phase 2/35 trials · 1 met primary
Phase 2/3	NCT05184101	Aug → Dec 2023	COVID-19	Australian National University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2/3	NCT05204550	Jan 2023 → Dec 2024	COVID-19	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 2/3	NCT05255848	Jun → Aug 2022	pneumonia	Lady Reading Hospital, Pakistan	Unknown	No outcome recorded
Phase 2/3	NCT04545541	Nov 2020 → Apr 2024	COVID-19, respiratory failure	Australian National University	Completed	No outcome recorded
Phase 2/3	NCT04635241	Jun 2020 → Nov 2023	COVID-19	Australian National University	Completed	Met primary
Phase 313 trials · 2 missed
Phase 3	NCT05848713	Oct 2023 → Mar 2028 expected	pneumonia	University of Manitoba	Recruiting	No outcome recorded
Phase 3	NCT04861922	May 2021 → Dec 2023	gram-negative bacterial infections, infectious disease with sepsis	The Third Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 3	NCT04528888	Nov 2020 → Jun 2021	COVID-19, blood coagulation disease, viral pneumonia	Massimo Girardis	Unknown	No outcome recorded
Phase 3	NCT04485429	Jul 2020 → Dec 2022	COVID-19	D'Or Institute for Research and Education	Withdrawn	No outcome recorded
Phase 3	NCT04444700	Jul 2020 → May 2021	COVID-19, blood coagulation disease, severe acute respiratory syndrome, venous thromboembolism	University of Sao Paulo General Hospital	Completed	Missed primary
Phase 3	NCT04362085	May 2020 → May 2021	COVID-19	Unity Health Toronto	Completed	Missed primary
Phase 3	NCT03465085	Feb 2016 → Jan 2018	acute respiratory distress syndrome, severe acute respiratory syndrome	Beni-Suef University	Completed	No outcome recorded
Phase 3	NCT01773083	Oct 2013 → Oct 2016	lung disorder	Academic Medical Center - University of Amsterdam	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02135770	Jan 2013 → Jun 2014	infectious disease with sepsis	Indonesia University	Completed	No outcome recorded
Phase 3	NCT00911157	Jun 2008 → Nov 2009	venous thromboembolism	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00981409	Jul 2007 → Dec 2008	pulmonary embolism	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00182364	Feb 2003 → Feb 2004	venous thromboembolism	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 3	NCT00182403	Sep 1998 → May 2004	pulmonary embolism, venous thromboembolism	McMaster University	Completed	No outcome recorded

Phase 415 trials · 2 met primary · 2 missed
Phase 4	NCT07609771	Jun → Nov 2026 expected	acute pancreatitis	Allied Hospital Faisalabad	Not yet recruiting	No outcome recorded
Phase 4	NCT06174961	Sep 2023 → Feb 2024	blood coagulation disease	Kristian Karstoft	Completed	No outcome recorded
Phase 4	NCT05247424	Mar 2022 → Feb 2025	ST-elevation myocardial infarction	University Medical Centre Ljubljana	Completed	No outcome recorded
Phase 4	NCT04406389	Oct 2020 → Apr 2021	COVID-19	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04409834	Aug 2020 → Mar 2022	COVID-19, thrombotic disease, venous thromboembolism	The TIMI Study Group	Completed	Mixed
Phase 4	NCT04394377	Jun 2020 → Mar 2021	COVID-19	Brazilian Clinical Research Institute	Completed	Missed primary
Phase 4	NCT03664180	Jan 2019 → Nov 2022	ST-elevation myocardial infarction	Beijing Anzhen Hospital	Completed	Missed primary
Phase 4	NCT03426982	Mar → Oct 2018	bleeding disorder, vascular-type, myocardial infarction, stroke disorder, venous thromboembolism	Wuhan Asia Heart Hospital	Unknown	No outcome recorded
Phase 4	NCT02570243	Feb 2015 → Sep 2017	—	University of Patras	Completed	Met primary
Phase 4	NCT01980316	Apr 2010 → Aug 2011	cardiovascular disorder	Xinfeng Liu	Completed	No outcome recorded
Phase 4	NCT00735280	Aug 2008 → Mar 2010	coronary artery disorder	German Heart Center Munich	Completed	Met primary
Phase 4	NCT01634438	Jul 2008 → Dec 2010	—	University of Alberta	Completed	No outcome recorded
Phase 4	NCT00253396	Oct 2005 → Jan 2007	—	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT00439855	Sep 2003 → Feb 2006	coronary artery disorder	Triemli Hospital	Completed	No outcome recorded
Phase 4	NCT00253851	Jul 2003 → May 2011	osteoarthritis, venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded

Phase not applicable9 trials
—	NCT07361783	Jan 2026 → Dec 2029 expected	ST-elevation myocardial infarction	Chen Jing	Recruiting	No outcome recorded
—	NCT06753786	Oct 2024 → Dec 2028 expected	intracerebral hemorrhage, pulmonary embolism, venous thromboembolism	Pirogov Russian National Research Medical University	Recruiting	No outcome recorded
—	NCT06276010	Jul 2024 → Nov 2026 expected	—	Xiaotong Hou	Recruiting	No outcome recorded
—	NCT06275555	Jun 2024 → Dec 2026 expected	—	Xiaotong Hou	Recruiting	No outcome recorded
—	NCT04139525	Sep 2020 → Dec 2022	end stage renal failure	Marija Malgaj Vrečko	Unknown	No outcome recorded
—	NCT04561648	Aug 2020 → Dec 2025	arterial occlusion	Instituto Nacional de Cardiologia Ignacio Chavez	Unknown	No outcome recorded
—	NCT04487990	Jun 2020 → Mar 2021	COVID-19, acute kidney injury	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT04121611	Oct 2019 → Oct 2021	basilar artery occlusion	Sunnybrook Health Sciences Centre	Unknown	No outcome recorded
—	NCT01839578	May 2013 → Nov 2014	infectious disease with sepsis	Hospices Civils de Lyon	Unknown	No outcome recorded
Comparator or background therapy62 trials
Phase 1/2	NCT03000673 Comparator	May → Oct 2017	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT05959252 Comparator	May 2024 → Jun 2026 overdue	—	Sydney Local Health District	Recruiting	No outcome recorded
Phase 2	NCT05555641 Comparator	Dec 2022 → Oct 2024	—	Xiaobo Yang, MD	Unknown	No outcome recorded
Phase 2	NCT03854266 Comparator	Mar 2020 → Mar 2023	pulmonary embolism	University of Aarhus	Unknown	No outcome recorded
Phase 2	NCT03178864 Comparator	Mar 2019 → Oct 2022	cerebral sinovenous thrombosis	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT03772613 Comparator	Feb 2019 → Oct 2021	coronary artery disorder, hemorrhagic disease, ischemic disease	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT01662908 Comparator	Aug 2012 → Jan 2014	venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 2	NCT00911300 Comparator	Aug 2009 → Sep 2011	atrial fibrillation	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00818753 Comparator	Jan 2009 → Aug 2010	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00715455 Comparator	Oct 2007 → Oct 2008	coronary artery disorder	Regado Biosciences, Inc.	Completed	No outcome recorded
Phase 2	NCT00543400 Comparator	Sep 2007 → Apr 2009	coronary artery disorder	Momenta Pharmaceuticals, Inc.	Completed	Met primary
Phase 2	NCT00317395 Comparator	Jun 2006 → Oct 2008	coronary artery disorder	Sanofi	Completed	Missed primary
Phase 2/3	NCT05226442 Comparator	Dec 2021 → Jul 2024	blood coagulation disease	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT04486508 Background	Jul 2020 → Apr 2021	COVID-19	Rajaie Cardiovascular Medical and Research Center	Completed	Missed primary
Phase 3	NCT04401293 Comparator	Apr 2020 → May 2021	COVID-19	Northwell Health	Completed	No outcome recorded
Phase 3	NCT02448550 Comparator	May 2015 → May 2016	—	Kaiser Permanente	Terminated	No outcome recorded
Phase 3	NCT01913483 Comparator	Sep 2013 → Mar 2016	hemorrhagic disease, peripheral arterial disease	The Medicines Company	Terminated	Missed primary
Phase 3	NCT01962116 Comparator	Jun 2013 → Apr 2016	—	Centre Hospitalier Universitaire Dijon	Completed	Missed primary
Phase 3	NCT02091479 Comparator	Jan 2013 → Jun 2015	—	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT01780987 Comparator	Jan 2013 → Sep 2014	pulmonary embolism, venous thromboembolism	Pfizer	Completed	No outcome recorded
Phase 3	NCT01651780 Comparator	Oct 2012 → Jun 2015	aortic valve stenosis	The Medicines Company	Completed	Mixed
Phase 3	NCT01516840 Comparator	Mar 2012 → Dec 2013	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01516814 Comparator	Feb 2012 → Oct 2013	pulmonary embolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01166997 Comparator	Jul 2010 → Apr 2013	—	Boston Scientific Corporation	Completed	No outcome recorded
Phase 3	NCT00882635 Comparator	Oct 2008 → Jun 2012	acute myocardial infarction	Robert Welsh	Completed	No outcome recorded
Phase 3	NCT00718471 Comparator	Aug 2008 → Mar 2010	ST-elevation myocardial infarction	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT01465503 Comparator	Jan 2008 → Dec 2012	hemorrhagic disease	Clinica Mediterranea	Completed	No outcome recorded
Phase 3	NCT00464087 Comparator	Jun 2007 → Nov 2010	acute coronary syndrome	Medstar Health Research Institute	Completed	No outcome recorded
Phase 3	NCT00451412 Comparator	Jan 2007 → Jun 2009	venous thromboembolism	Novartis	Completed	No outcome recorded
Phase 3	NCT00182143 Comparator	May 2006 → Jun 2010	venous thromboembolism	McMaster University	Completed	No outcome recorded
Phase 3	NCT00238667 Comparator	Nov 2005 → May 2014	carotid artery dissection, stroke disorder, vertebral artery dissection	St George's, University of London	Completed	No outcome recorded
Phase 3	NCT00433966 Comparator	Mar 2005 → Jun 2008	myocardial infarction	Cardiovascular Research Foundation	Completed	No outcome recorded
Phase 3	NCT00628576 Comparator	Oct 1993 → Jun 2004	venous thromboembolism	Aalborg University Hospital	Completed	No outcome recorded
Phase 4	NCT06442267 Comparator	Jul 2024 → Jan 2027 expected	hemorrhagic disease, respiratory failure, thrombotic disease	Medical University of Vienna	Recruiting	No outcome recorded
Phase 4	NCT06375616 Comparator	Apr 2024 → Apr 2027 expected	infectious disease with sepsis	Shen Lei	Not yet recruiting	No outcome recorded
Phase 4	NCT05493163 Comparator	Oct 2022 → Mar 2026	pulmonary embolism	Faculty Hospital Kralovske Vinohrady	Completed	No outcome recorded
Phase 4	NCT05191290 Comparator	Jan → Dec 2022	—	University Medical Centre Ljubljana	Completed	No outcome recorded
Phase 4	NCT04635839 Comparator	Dec 2020 → Mar 2022	pregnancy disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT03988842 Background	Jul 2019 → Apr 2020	acute cor pulmonale, pulmonary embolism, pulmonary embolism and infarction	Victor Tapson, MD	Terminated	No outcome recorded
Phase 4	NCT03965208 Comparator	May 2019 → Dec 2020	—	Legacy Health System	Unknown	No outcome recorded
Phase 4	NCT03318393 Comparator	Mar 2018 → Oct 2021	childhood acute lymphoblastic leukemia	University of Texas Southwestern Medical Center	Completed	Missed primary
Phase 4	NCT02957877 Comparator	Mar 2016 → May 2018	end stage renal failure	Alice Ho Miu Ling Nethersole Hospital	Unknown	No outcome recorded
Phase 4	NCT02860299 Comparator	Feb 2015 → Jan 2016	acute kidney injury	Centre Hospitalier Universitaire Dijon	Completed	No outcome recorded
Phase 4	NCT01930396 Comparator	Sep 2013 → Sep 2016	chronic renal failure syndrome	Christine Ribic	Completed	No outcome recorded
Phase 4	NCT01519518 Comparator	Feb 2012 → Dec 2013	ST-elevation myocardial infarction	Liverpool Heart and Chest Hospital NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT01318811 Comparator	Mar 2011 → Apr 2016	acute kidney injury, heart failure	Vanderbilt University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01228292 Comparator	Jan 2011 → Jan 2012	acute kidney injury	University Hospital, Antwerp	Unknown	No outcome recorded
Phase 4	NCT01956955 Comparator	Jan 2011 → Dec 2013	—	Ataturk University	Unknown	No outcome recorded
Phase 4	NCT00445328 Comparator	Jun 2007 → Jul 2008	venous thromboembolism	Pfizer	Terminated	No outcome recorded
Phase 4	NCT00435487 Comparator	Jun 2007 → Dec 2008	intermediate coronary syndrome, myocardial infarction	Pfizer	Terminated	Met primary
Phase 4	NCT00262054 Comparator	Nov 2005 → Feb 2008	coronary artery disorder	German Heart Center Munich	Completed	Missed primary
Phase 4	NCT00790387 Comparator	Jun 2004 → Dec 2005	acute coronary syndrome	The Prince Charles Hospital	Completed	No outcome recorded
Phase 4	NCT00796692 Comparator	Jun 2002 → Feb 2006	pulmonary embolism, thrombotic disease, venous thromboembolism	Beijing Chao Yang Hospital	Completed	No outcome recorded
—	NCT07548346 Background	Jul 2026 → Jan 2029 expected	cerebral sinovenous thrombosis	Middle East North Africa Stroke and Interventional Neurotherapies Organization	Not yet recruiting	No outcome recorded
—	NCT07618858 Comparator	Jun → Dec 2026 expected	end stage renal failure	University Medical Centre Ljubljana	Not yet recruiting	No outcome recorded
—	NCT06861374 Comparator	May 2025 → Mar 2028 expected	ST-elevation myocardial infarction	First Affiliated Hospital Xi'an Jiaotong University	Not yet recruiting	No outcome recorded
—	NCT07374978 Comparator	Jul 2023 → May 2025	pulmonary embolism	Ain Shams University	Completed	No outcome recorded
—	NCT04049591 Comparator	Mar 2022 → Oct 2024 overdue	cardiovascular disorder	Population Health Research Institute	Recruiting	No outcome recorded
—	NCT05148026 Comparator	Nov 2021 → Jul 2025	acute kidney injury, acute respiratory distress syndrome	University of Milano Bicocca	Completed	No outcome recorded
—	NCT04925167 Comparator	Jul 2021 → Dec 2023	respiratory failure	Beijing Chao Yang Hospital	Completed	No outcome recorded
—	NCT05237726 Comparator	Apr 2020 → Feb 2022	—	King Abdullah International Medical Research Center	Completed	No outcome recorded
—	NCT00669721 Comparator	Mar → Jun 2008	kidney failure	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Unknown	No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 125 sources stand behind the page.

Field	Value	Cited text
Known as	HEPARIN CALCIUM	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201513 ↗
Known as	Calciparine	“Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days” NCT04344756 ↗
Known as	Ecasolv	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201513 ↗
Known as	Heparin calcium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201513 ↗
Known as	Heparinum calcicum	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201513 ↗
Known as	Héparine Sodique Choay	“Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days” NCT04344756 ↗
Known as	UFH	“The patients will be allocated by randomisation in equal proportions to the two treatment groups receiving UFH (70 units/kg prior to the procedure) or bivalirudin (bolus of...” NCT01519518 ↗ 37 “AIMS: Although a 140 U/kg dose of unfractionated heparin (UFH) was comparable with bivalirudin in terms of net clinical outcome in the Intracoronary Stenting and Antithrombotic...” PMID 20805113 ↗ Aug 2010 “Systemic infusion of unfractionated heparin (UFH) is the standard anticoagulation technique for continuous renal replacement therapy (CRRT) during extracorporeal membrane...” PMID 31045918 ↗ Mar 2020 “Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE” NCT04409834 ↗ “therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first.” NCT05848713 ↗ “Standard anticoagulation therapy consisting of intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) during the acute phase” NCT07548346 ↗ “Patients are randomized before diagnostic catheterization to receive intravenously either 100IU/Kg or 50 IU/Kg of unfractionated heparin (UFH) in a 1:1 ratio.” NCT02570243 ↗ “Every patient will have 2 HD procedures with PES-PVP membrane in a randomized order: 1 with unfractionated heparin (UFH) and 1 with 8% trisodium citrate.” NCT04139525 ↗ “Participants were randomly allocated to the standard dose of UFH (5,000 units subcutaneously every 12 hours) or the gestational age-based dose of UFH” PMID 38743958 ↗ May 2024 “The experimental group was required to be given an intravenous injection of 100 U/kg of UFH within 10 minutes after randomization” NCT07361783 ↗ “Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure.” NCT01465503 ↗ Show 27 more sources
Known as	Unfractionated Heparin	“Unfractionated heparin is the most negatively charged biological molecule known, heparin has a strong ability to interfere with the functioning of positively charged molecules.” NCT04313790 ↗ 114 “therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first.” NCT05848713 ↗ “Before randomization, all patients are treated with intravenous unfractionated heparin (to a target aPTT of 70-90 s) or subcutaneous LMWH (the full therapeutic dose).” NCT05493163 ↗ “Standard anticoagulation therapy consisting of intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) during the acute phase” NCT07548346 ↗ “Unfractionated heparin was administered subcutaneously as an initial dose of 333 U/kg, followed by a fixed dose of 250 U/kg every 12 hours (n = 345).” PMID 16926353 ↗ Aug 2006 “OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis” NCT00669721 ↗ “The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion.” NCT04362085 ↗ “Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value” NCT04485429 ↗ “unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist” NCT03178864 ↗ “intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL” NCT02091479 ↗ “However, the optimal dose of unfractionated heparin (UFH) for elective PCI is currently unclear.” PMID 41443541 ↗ Dec 2025 Show 104 more sources
Known as	Unfractionated Heparin, LEO laboratories Ltd, MA #PL 0043/0041R	“Unfractionated Heparin, LEO laboratories Ltd, MA #PL 0043/0041R” NCT01228292 ↗
Known as	Uniparin ca	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201513 ↗
Action	Activate	“Antithrombin-III activator” CHEMBL1201513 ↗
Action	Inhibit	“Heparin also have an anti-inflammatory effect through downregulates nuclear factor kappa B and tumor necrosis factor alpha.” NCT02135770 ↗
Modality	Other / unclassified	“unfractionated heparin (UFH)” NCT00182143 ↗
Route	Intravenous	“Intravenous Unfractionated Heparin” NCT00133731 ↗
Target	SERPINC1	“Antithrombin-III activator” CHEMBL1201513 ↗